Orthocell (ASX:OCC) said its revenue rose almost 15% to AU$2 million in the September quarter from AU$1.8 million in the same period last year, according to a Monday filing with the Australian bourse.
The regenerative medicine company attributed its second straight quarter of record revenue to robust sales of Striate+ and Remplir. It expects to obtain US Food and Drug Administration approval for Remplir in the first quarter of 2025.
Orthocell's shares were up more than 4% in recent Monday trade and earlier hit a new 52-week high.
Price (AUD): $0.48, Change: $+0.02, Percent Change: +4.35%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.